Abstract library

81 results for "zoledronic acid".
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni
#277 Metastatic Gastrinoma Co-secreting PTHrP and ACTH
Introduction: Metastatic gastrinoma is occasionally associated with tumor secretion of functioning peptides, resulting in additional syndromes.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC
Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Sofie M.D.A. Van Binnebeek
#750 Management of Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor
Introduction: Nonfunctional NETs themselves present in generally two ways, either with symptoms caused by the tumor compression of other organs, or found by imaging test performed for other reasons.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Ivan Vasiliev
#1862 Biphosphonates in Metastatic Bone Disease of Neuroendocrine Neoplasms
Introduction: Metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs) is associated with a more aggressive behaviour
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: MD Krystallenia Alexandraki
Keywords: bone disease
#2949 Sunitinib May Be an Effective Treatment for Hypercalcemia Due To a Metastatic Pancreatic Neuroendocrine Tumor
Introduction: Malignant hypercalcemia due to neuroendocrine tumor(NET) is rare, and only a few reports are available in the literature.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Prof. Huang-Ying Tan
Authors: Wang C, Qi Z, Tan H D, Tan H Y, ...
#119 Valproic acid induces apoptosis-mediated cell death of the ileal carcinoid cell line GOT1
Introduction: Downregulation of tumor suppressor genes, evasion from apoptosis, and reduced differentiation are hallmarks of cancer that can be due to abnormal epigenetic control. Histone deacetylase (HDAC) is an enzyme involved in the deacetylation of histone proteins, resulting in chromatin remodelling and altered gene transcription. HDAC inhibitors are emerging as useful anticancer drugs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Yvonne Arvidsson
Authors: Arvidsson Y, Ahlman H, Nilsson O, ...
#325 Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results
Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Baudin
#925 Negative Urinary Fractionated Metanephrines and Elevated Urinary Vanillylmandelic Acid in a Patient with a Sympathetic Paravesical Paraganglioma
Introduction: Paragangliomas have hereditary and sporadic presentations.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Edwin A Wandurraga
Authors: Wandurraga E A, MarĂ­n L F, ...
#595 A Single Fasting Plasma 5-HIAA Value Correlates with 24-Hour Urinary 5-HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumors (NETs)
Introduction: 5-hydoxyindoleacetic acid (5-HIAA) is used for the evaluation of neuroendocrine tumors (NETs), however, the current 5-HIAA assay requires a 24-hour urine collection which is inconvenient.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Eugene Woltering